112 related articles for article (PubMed ID: 9920036)
1. Iloprost treatment in systemic sclerosis: comment on the concise communication by Tedeschi et al.
Braun J; Sieper J; Riemekasten G; Hiepe F
Arthritis Rheum; 1999 Jan; 42(1):196-8. PubMed ID: 9920036
[No Abstract] [Full Text] [Related]
2. Diffuse cutaneous systemic sclerosis treated with intravenous iloprost.
Foti C; Cassano N; Conserva A; Coviello C; De Meo M; Vena GA
Clin Exp Dermatol; 2004 May; 29(3):321-3. PubMed ID: 15115528
[No Abstract] [Full Text] [Related]
3. Thrombotic events in patients with systemic sclerosis treated with iloprost.
Tedeschi A; Meroni PL; Del Papa N; Salmaso C; Boschetti C; Miadonna A
Arthritis Rheum; 1998 Mar; 41(3):559-60. PubMed ID: 9506585
[No Abstract] [Full Text] [Related]
4. [Iloprost for the treatment of systemic sclerosis].
Hachulla E; Launay D; Hatron PY
Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
[TBL] [Abstract][Full Text] [Related]
5. Ischemic finger ulcer as a presenting symptom of systemic sclerosis.
Balbir-Gurman A; Markovits D; Nahir AM; Rozin A; Braun-Moscovici Y
Isr Med Assoc J; 2005 Aug; 7(8):531-2. PubMed ID: 16106783
[No Abstract] [Full Text] [Related]
6. Effects of iloprost on microvascular structure assessed by nailfold videocapillaroscopy: a pilot study.
Shah P; Murray AK; Moore TL; Herrick AL
J Rheumatol; 2011 Sep; 38(9):2079-80. PubMed ID: 21885525
[No Abstract] [Full Text] [Related]
7. Possible role of iloprost (stable analog of PG12) in promoting neoangiogenesis in systemic sclerosis.
Faggioli P; Giani L; Mazzone A
Clin Exp Rheumatol; 2006; 24(2):220-1. PubMed ID: 16762173
[No Abstract] [Full Text] [Related]
8. [Iloprost therapy in systemic sclerosis].
Bali G; Aberer E
Hautarzt; 2003 Sep; 54(9):845-51. PubMed ID: 12955262
[TBL] [Abstract][Full Text] [Related]
9. [Digital ulcers in systemic sclerosis].
Guillevin L
Presse Med; 2008 Apr; 37(4 Pt 2):735-6. PubMed ID: 18258409
[No Abstract] [Full Text] [Related]
10. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
[TBL] [Abstract][Full Text] [Related]
11. Axonal degeneration in systemic sclerosis can be reverted by factors improving tissue oxygenation.
Provitera V; Nolano M; Pappone N; Lubrano E; Stancanelli A; Lanzillo B; Santoro L
Rheumatology (Oxford); 2007 Nov; 46(11):1739-41. PubMed ID: 17938133
[No Abstract] [Full Text] [Related]
12. Coagulative modifications in patients with systemic sclerosis treated with iloprost or nifedipine.
Candela M; Pansoni A; Jannino L; Menditto VG; Natalini M; Ravaglia F; Da Lio L; Scorza R; Gabrielli A; Danieli G
Ann Ital Med Int; 2001; 16(3):170-4. PubMed ID: 11692906
[TBL] [Abstract][Full Text] [Related]
13. Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis.
Marczin N; Riedel B; Royston D; Yacoub M
Lancet; 1998 Aug; 352(9125):405-6. PubMed ID: 9717956
[No Abstract] [Full Text] [Related]
14. Antioxidant effect of Iloprost: current knowledge and therapeutic implications for systemic sclerosis.
Erre GL; Passiu G
Reumatismo; 2009; 61(2):90-7. PubMed ID: 19633795
[TBL] [Abstract][Full Text] [Related]
15. [Digital necrosis in scleroderma].
Fain O
Rev Prat; 2007 Feb; 57(4):359. PubMed ID: 17455736
[No Abstract] [Full Text] [Related]
16. A new digital health tool for the telemonitoring of patients with scleroderma during iloprost administration: a feasibility and acceptability study.
Faggioli P; Zaccara E; Castelnovo L; Bompane D; Tamburello A; Lurati A; Laria A; Gangemi D; Giani M; Gnani D; Di Giorgi M; Iura K; Grandelis F; Piazza R; Piana T; Zizzo G; Mazzone A
Eur Rev Med Pharmacol Sci; 2023 Jan; 27(2):799-804. PubMed ID: 36734722
[TBL] [Abstract][Full Text] [Related]
17. The social costs of digital ulcer management in sclerodema patients: an observational Italian pilot study.
Cozzi F; Tiso F; Lopatriello S; Ciprian L; Sfriso P; Berto P; Punzi L
Joint Bone Spine; 2010 Jan; 77(1):83-4. PubMed ID: 20031470
[No Abstract] [Full Text] [Related]
18. The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia.
Mazzone A; Cusa C; Bucci L; Vezzoli M; Ghio S; Buggia I; Regazzi MB; Fossati G; Mazzucchelli I; Gritti D
Eur J Clin Invest; 1999 Jan; 29(1):1-5. PubMed ID: 10092981
[TBL] [Abstract][Full Text] [Related]
19. Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost.
Caramaschi P; Dalla Gassa A; Prati D; Barausse G; Tinazzi I; Ravagnani V; Confente S; Biasi D
Rheumatol Int; 2012 Jul; 32(7):1933-8. PubMed ID: 21448643
[TBL] [Abstract][Full Text] [Related]
20. Prostacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrations.
Rehberger P; Beckheinrich-Mrowka P; Haustein UF; Sticherling M
Acta Derm Venereol; 2009; 89(3):245-9. PubMed ID: 19479119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
